Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

AMLX

Amylyx Pharmaceuticals Inc

Last Close
May 17 • 04:00PM ET
1.83
Dollar change
0.00
Percentage change
0.00 		%
Held by: VTI VB IWM VBK VXF IWO IBB FTLS SCHA VTWO
IndexRUT P/E- EPS (ttm)-1.07 Insider Own30.26% Shs Outstand67.71M Perf Week4.27%
Market Cap124.46M Forward P/E- EPS next Y-1.44 Insider Trans-0.16% Shs Float47.42M Perf Month-7.58%
Income-71.09M PEG- EPS next Q-0.73 Inst Own71.26% Short Float17.96% Perf Quarter-88.48%
Sales398.00M P/S0.31 EPS this Y-508.33% Inst Trans32.39% Short Ratio2.40 Perf Half Y-86.01%
Book/sh4.77 P/B0.38 EPS next Y49.68% ROA-17.23% Short Interest8.51M Perf Year-93.41%
Cash/sh5.49 P/C0.33 EPS next 5Y- ROE-21.00% 52W Range1.70 - 28.13 Perf YTD-87.57%
Dividend Est.- P/FCF8.06 EPS past 5Y- ROI-21.82% 52W High-93.49% Beta-0.65
Dividend TTM- Quick Ratio4.48 Sales past 5Y2300.59% Gross Margin65.39% 52W Low7.65% ATR (14)0.19
Dividend Ex-DateMar 28, 2018 Current Ratio4.48 EPS Y/Y TTM32.69% Oper. Margin-20.42% RSI (14)29.71 Volatility5.00% 7.16%
Employees384 Debt/Eq0.01 Sales Y/Y TTM324.95% Profit Margin-17.86% Recom2.71 Target Price4.08
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-7986.04% Payout0.00% Rel Volume0.35 Prev Close1.83
Sales Surprise-9.91% EPS Surprise-43650.00% Sales Q/Q24.10% EarningsMay 09 BMO Avg Volume3.54M Price1.83
SMA20-3.08% SMA50-32.81% SMA200-86.44% Trades Volume1,222,173 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-18-24Downgrade Mizuho Buy → Neutral $32 → $4
Mar-11-24Downgrade Robert W. Baird Outperform → Neutral $37 → $4
Mar-11-24Downgrade Leerink Partners Outperform → Market Perform $27 → $4
Mar-08-24Downgrade Goldman Buy → Neutral
Mar-08-24Downgrade Evercore ISI Outperform → In-line
Jan-03-24Initiated Robert W. Baird Outperform $37
Dec-12-23Initiated Deutsche Bank Buy $36
Jul-24-23Upgrade Goldman Neutral → Buy $45 → $49
Mar-31-23Initiated Mizuho Buy $52
Jan-05-23Initiated BofA Securities Buy $50
Show Previous Ratings
May-14-24 07:25AM
Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating
(MT Newswires)
May-10-24 03:54PM
Amylyx Pharmaceuticals Reports Q1 2024 Financial Results
(GuruFocus.com) -7.14%
12:47PM
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript
(Insider Monkey)
May-09-24 08:15AM
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
07:00AM
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
(Business Wire)
09:00AM Loading…
May-08-24 09:00AM
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
(Business Wire)
May-02-24 09:00AM
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
(Business Wire)
Apr-30-24 12:02PM
Trials to watch: Four ALS drugs to keep an eye on
(Clinical Trials Arena)
Apr-10-24 03:14PM
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
(Benzinga) -7.87%
09:00AM
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
(Business Wire)
Apr-08-24 09:00AM
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
(Business Wire)
Apr-04-24 01:20PM
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
(Zacks)
10:05AM
ALS drug will be pulled from US market after study showed patients didn't benefit
(Associated Press Finance)
07:52AM
UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets
(Reuters)
07:43AM
Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market
(Barrons.com)
07:07AM Loading…
07:07AM
Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets
(Reuters)
07:00AM
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
(Business Wire)
06:09AM
Amylyx to pull ALS drug from market in rare move
(BioPharma Dive)
Apr-03-24 05:45AM
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
(PR Newswire)
Apr-01-24 07:30PM
Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
(GlobeNewswire)
Mar-27-24 07:36AM
European study finds popular ALS drug ineffective
(BioPharma Dive) +5.11%
Mar-25-24 02:33PM
Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman
(GlobeNewswire)
Mar-14-24 06:49PM
3 Pharma Stocks to Sell in March Before They Crash & Burn
(InvestorPlace) -7.85%
09:00AM
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
(Business Wire)
Mar-13-24 10:00AM
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
(PR Newswire)
09:03AM
Analysts on Wall Street Lower Ratings for These 10 Stocks
(Insider Monkey)
Mar-12-24 07:55AM
After surprise trial failure, ALS doctors brace for one less treatment option
(BioPharma Dive) -9.47%
Mar-11-24 12:34PM
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
(Zacks) +13.10%
07:45AM
Amylyx CEOs look for a path forward following major setback
(BioPharma Dive)
Mar-10-24 08:00AM
Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.
(The Wall Street Journal)
06:27PM Loading…
Mar-08-24 06:27PM
Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations
(Business Wire) -82.29%
04:05PM
Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure
(Investor's Business Daily)
11:30AM
Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work
(Associated Press Finance)
10:20AM
Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future
(Barrons.com)
10:12AM
Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test
(Investor's Business Daily)
09:38AM
10 Biotech Stocks with Huge Potential
(Insider Monkey)
09:26AM
Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
(GlobeNewswire)
07:07AM
Amylyx's ALS drug fails in late-stage confirmatory study
(Reuters)
07:00AM
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
(Business Wire)
02:05AM
Amylyx ALS drug fails crucial study, putting companys future in doubt
(BioPharma Dive)
Feb-27-24 05:45AM
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
(PR Newswire) +8.20%
Feb-26-24 11:39AM
AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline
(GlobeNewswire)
Feb-25-24 06:30AM
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
(InvestorPlace)
Feb-23-24 04:05PM
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
(Business Wire)
10:30AM
AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options
(GlobeNewswire)
10:10AM
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript
(Insider Monkey)
09:00AM
AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Amylyx Pharmaceuticals, Inc.
(Business Wire)
05:45AM
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX
(PR Newswire)
Feb-22-24 06:57PM
Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman
(GlobeNewswire) +21.10%
04:10PM
Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter
(Investor's Business Daily)
08:15AM
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates
(Zacks)
07:35AM
Amylyx Pharmaceuticals Inc (AMLX) Reports Robust Revenue Growth and Net Income for Full Year 2023
(GuruFocus.com)
07:00AM
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
(Business Wire)
Feb-20-24 05:45AM
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
(PR Newswire) -6.11%
Feb-19-24 12:40PM
Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman
(GlobeNewswire)
Feb-15-24 04:05PM
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
(Business Wire)
02:13PM
Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman
(GlobeNewswire)
09:00AM
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
(Business Wire)
Feb-13-24 09:16PM
Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations
(Business Wire) -7.94%
12:58PM
Get Rich Quick With These 3 Biotech Stocks to Buy Now
(InvestorPlace)
Feb-12-24 08:09PM
Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman
(GlobeNewswire)
11:09AM
Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
(GlobeNewswire)
Feb-08-24 09:00AM
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
(Business Wire)
Jan-26-24 03:57PM
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
(InvestorPlace)
Jan-21-24 01:16PM
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
(InvestorPlace)
Jan-14-24 12:54PM
7 Healthcare Stocks Taking Medicine to the Next Level
(InvestorPlace)
Jan-05-24 05:34AM
2 Biotech Stocks With Huge Catalysts in 2024
(Motley Fool)
Dec-26-23 07:02PM
5 Best IPO Stocks to Buy Heading into 2024
(Insider Monkey)
08:48AM
Is Amylyx (AMLX) Stock a Solid Choice Right Now?
(Zacks)
Dec-22-23 09:00AM
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
(Business Wire)
Dec-11-23 08:36AM
Implied Volatility Surging for Amylyx (AMLX) Stock Options
(Zacks)
Dec-04-23 09:00AM
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
(Business Wire)
Nov-29-23 05:15PM
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +5.19%
Nov-28-23 08:48AM
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
(InvestorPlace)
07:00AM
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
(Business Wire)
Nov-27-23 09:00AM
RELYVRIO and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
(Business Wire)
Nov-21-23 09:00AM
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
(Business Wire)
Nov-12-23 11:59AM
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-10-23 12:26AM
Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
Nov-09-23 05:04PM
Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024
(Investor's Business Daily) -31.89%
12:12PM
Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles
(Investor's Business Daily)
08:05AM
Amylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue Growth
(GuruFocus.com)
07:00AM
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
(Business Wire)
Nov-04-23 12:16PM
5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
(Insider Monkey)
Nov-02-23 10:00AM
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
(Zacks) +5.38%
09:00AM
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
(Business Wire)
Oct-19-23 09:00AM
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium
(Business Wire)
Oct-18-23 08:30AM
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
(Zacks)
Oct-13-23 08:26AM
UPDATE 1-EU regulator declines to recommend Amylyx' ALS drug
(Reuters)
07:55AM
EU regulator declines to recommend Amylyx' ALS therapy
(Reuters)
07:45AM
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
(Business Wire)
Oct-11-23 08:07AM
PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?
(Zacks)
Oct-10-23 09:45AM
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
(Motley Fool)
09:12AM
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
(Business Wire)
Oct-05-23 05:26PM
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
(Business Wire)
Oct-02-23 09:00AM
RELYVRIO and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
(Business Wire)
Sep-29-23 12:43PM
25 Biggest Stocks with Negative Beta
(Insider Monkey)
02:54AM
14 Best Depressed Stocks To Buy Now
(Insider Monkey)
Sep-20-23 09:02AM
Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?
(Zacks)
Sep-05-23 09:00AM
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
(Business Wire) -5.41%
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quimi DaphneDirectorMay 15 '24Buy1.892,2504,2525,000May 16 07:37 PM
Mazzariello GinaChief Legal OfficerMay 15 '24Sale1.8810,45519,654151,477May 16 07:36 PM
Quimi DaphneDirectorMay 14 '24Buy1.892,7505,1842,750May 16 07:37 PM
Klee Justin B.Co-Chief Executive OfficerMar 05 '24Sale18.734,13577,4402,959,308Mar 07 04:05 PM
Cohen Joshua BCo-Chief Executive OfficerMar 05 '24Sale18.734,13577,4403,023,002Mar 07 04:05 PM
FRATES JAMES MChief Financial OfficerMar 05 '24Sale18.731,79233,560134,784Mar 07 04:05 PM
Mazzariello GinaChief Legal OfficerMar 05 '24Sale18.731,54028,84181,372Mar 07 04:05 PM
Mazzariello GinaChief Legal OfficerFeb 23 '24Sale18.762,83853,23146,245Feb 27 05:59 PM
Klee Justin B.Co-Chief Executive OfficerJan 09 '24Sale16.335,84195,3722,836,776Jan 11 05:11 PM
Cohen Joshua BCo-Chief Executive OfficerJan 09 '24Sale16.335,84195,3722,900,470Jan 11 05:10 PM
Yeramian Patrick DChief Medical OfficerJan 09 '24Sale16.332,81245,915205,605Jan 11 05:04 PM
FRATES JAMES MChief Financial OfficerJan 09 '24Sale16.332,71644,347112,035Jan 11 05:11 PM
Olinger MargaretChief Commercial OfficerDec 27 '23Option Exercise0.3725,0009,250276,108Dec 29 04:07 PM
Firestone KarenDirectorDec 15 '23Buy14.974,00059,8805,000Dec 19 04:37 PM
Cohen Joshua BCo-Chief Executive OfficerNov 16 '23Option Exercise1.5763,694100,0002,906,311Nov 20 08:20 PM
FRATES JAMES MChief Financial OfficerAug 23 '23Option Exercise6.8818,165124,975106,341Aug 24 04:15 PM
Mazzariello GinaChief Legal OfficerAug 15 '23Sale20.886,164128,68649,083Aug 17 04:35 PM
Olinger MargaretChief Commercial OfficerJul 12 '23Option Exercise0.3720,0007,400251,108Jul 14 04:20 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

AUPH

Aurinia Pharmaceuticals Inc

Last Close
May 17 • 04:00PM ET
5.76
Dollar change
-0.01
Percentage change
-0.17 		%
Held by: IWM IWO IBB VTWO VHT VTWG SBIO PRFZ VT FHLC
IndexRUT P/E- EPS (ttm)-0.44 Insider Own11.59% Shs Outstand143.83M Perf Week14.74%
Market Cap823.80M Forward P/E12.17 EPS next Y0.47 Insider Trans-1.92% Shs Float126.45M Perf Month19.75%
Income-62.56M PEG- EPS next Q0.01 Inst Own37.67% Short Float8.11% Perf Quarter-1.54%
Sales191.41M P/S4.30 EPS this Y112.96% Inst Trans9.06% Short Ratio6.05 Perf Half Y-29.41%
Book/sh2.50 P/B2.30 EPS next Y576.19% ROA-12.92% Short Interest10.26M Perf Year-46.22%
Cash/sh2.24 P/C2.58 EPS next 5Y- ROE-16.69% 52W Range4.71 - 12.43 Perf YTD-35.93%
Dividend Est.- P/FCF- EPS past 5Y6.35% ROI-14.44% 52W High-53.66% Beta1.43
Dividend TTM- Quick Ratio5.05 Sales past 5Y3168.98% Gross Margin88.59% 52W Low22.29% ATR (14)0.24
Dividend Ex-Date- Current Ratio5.60 EPS Y/Y TTM35.94% Oper. Margin-33.81% RSI (14)69.62 Volatility5.18% 4.69%
Employees300 Debt/Eq0.25 Sales Y/Y TTM30.37% Profit Margin-32.69% Recom1.62 Target Price10.14
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q59.39% Payout- Rel Volume1.38 Prev Close5.77
Sales Surprise6.86% EPS Surprise48.79% Sales Q/Q46.19% EarningsMay 02 BMO Avg Volume1.70M Price5.76
SMA2012.47% SMA5012.71% SMA200-22.79% Trades Volume2,332,457 Change-0.17%
Date Action Analyst Rating Change Price Target Change
Nov-04-22Downgrade Oppenheimer Outperform → Perform
May-05-22Resumed Cantor Fitzgerald Overweight $34 → $25
Dec-10-21Upgrade Oppenheimer Perform → Outperform $33 → $31
Oct-28-21Downgrade Oppenheimer Outperform → Perform $32
Jan-25-21Reiterated H.C. Wainwright Buy $30 → $35
Nov-03-20Reiterated H.C. Wainwright Buy $34 → $28
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
Show Previous Ratings
May-14-24 06:00AM
Analysis Showing LUPKYNIS is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024
(Business Wire)
May-09-24 06:00AM
Aurinia Presents Data Reinforcing LUPKYNIS Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
(Business Wire)
May-07-24 09:55AM
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
(Zacks)
06:00AM
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
(Business Wire)
May-03-24 01:02PM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
(Insider Monkey)
10:56AM Loading…
May-02-24 10:56AM
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
07:10AM
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
06:10AM
Aurinia: Q1 Earnings Snapshot
(Associated Press Finance)
06:00AM
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
(Business Wire)
May-01-24 06:00AM
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
(Business Wire)
Apr-30-24 06:00AM
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
(Business Wire)
Apr-16-24 10:48AM
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
(Business Wire)
Apr-15-24 06:00AM
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
(Business Wire)
Apr-09-24 06:00AM
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
(Business Wire)
Mar-17-24 05:20PM
11 Oversold Biotech Stocks To Buy Right Now
(Insider Monkey)
08:30AM Loading…
Feb-29-24 08:30AM
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
(Business Wire)
Feb-27-24 08:30AM
Aurinia to Participate in Upcoming Investor Healthcare Conferences
(Business Wire)
Feb-16-24 09:22AM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Feb-15-24 07:25AM
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
(Zacks) -24.47%
06:49AM
Aurinia Pharmaceuticals Inc (AUPH) Announces Year-End Financial Results and Strategic Initiatives
(GuruFocus.com)
06:32AM
Aurinia: Q4 Earnings Snapshot
(Associated Press Finance)
06:19AM
UPDATE 2-Aurinia Pharma fails to sell itself; to stop trials, cut jobs, buy back shares
(Reuters)
06:10AM
Aurinia to cut research after sale process fails to find a buyer
(BioPharma Dive)
06:07AM
Aurinia to stop R&D on immunotherapies to focus on kidney disease drug
(Reuters)
06:00AM
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
(Business Wire)
Feb-08-24 10:00AM
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
(Zacks)
Feb-05-24 08:30AM
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
(Business Wire)
Jan-18-24 04:30PM
Kane Biotech Announces Special Meeting of Shareholders
(GlobeNewswire)
Jan-05-24 06:00AM
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
(Business Wire)
Dec-28-23 09:40AM
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
(Zacks)
06:00AM Loading…
Dec-20-23 06:00AM
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
(Business Wire) -6.11%
Dec-10-23 06:59AM
This Small Pharma Could Be Targeted, But Would Be Fine Alone, Too
(TheStreet.com)
Nov-23-23 09:55AM
Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?
(Zacks)
Nov-20-23 09:40AM
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
(Zacks) +7.44%
Nov-13-23 06:00AM
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan
(Business Wire)
Nov-07-23 10:30AM
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS (voclosporin) for Patients with Lupus Nephritis at ACR 2023
(Business Wire)
09:55AM
Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?
(Zacks)
Nov-03-23 09:40AM
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
(Zacks)
08:46AM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-02-23 06:00PM
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis
(Business Wire) +10.52%
07:50AM
Aurinia Pharmaceuticals Inc (AUPH) Reports 60% Increase in Q3 Net Product Revenue
(GuruFocus.com)
07:15AM
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
06:10AM
Aurinia: Q3 Earnings Snapshot
(Associated Press Finance)
06:00AM
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
(Business Wire)
Oct-26-23 03:00PM
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
(Business Wire)
Oct-19-23 10:31AM
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
(Business Wire)
06:00AM
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
(Business Wire)
Oct-16-23 09:29AM
Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls
(Zacks) +5.32%
Oct-14-23 01:15PM
13 Stocks to Buy with Exponential Growth
(Insider Monkey)
Oct-13-23 12:00PM
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
(Business Wire)
Oct-12-23 12:13PM
Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study
(Zacks)
Oct-11-23 10:15AM
Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit
(Zacks)
Oct-09-23 11:10AM
J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC
(Zacks)
Oct-06-23 09:24AM
AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker
(Zacks)
Oct-04-23 08:17AM
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
(Zacks)
Oct-03-23 07:43AM
Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
(Zacks)
Sep-29-23 09:40AM
Are Medical Stocks Lagging Align Technology (ALGN) This Year?
(Zacks)
Sep-27-23 09:34AM
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
(Zacks)
Sep-26-23 10:56AM
AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
(Zacks)
Sep-21-23 06:00AM
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
(Business Wire)
Sep-18-23 08:52AM
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
(Zacks)
Sep-06-23 09:55AM
Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet
(Zacks)
Aug-25-23 09:40AM
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
(Zacks)
Aug-21-23 06:00AM
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
(Business Wire)
Aug-03-23 07:15AM
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
06:11AM
Aurinia: Q2 Earnings Snapshot
(AP Finance)
06:00AM
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
(Business Wire)
Jul-27-23 07:41AM
Institutions own 42% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares but individual investors control 56% of the company
(Simply Wall St.)
Jul-20-23 06:00AM
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
(Business Wire)
Jul-19-23 12:05PM
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
(Business Wire)
Jul-18-23 10:55AM
Aurinia Pharmaceuticals Stock Returns To A Rising Relative Strength
(Investor's Business Daily)
Jul-11-23 10:55AM
Aurinia Pharmaceuticals Stock Shows Rising Relative Strength
(Investor's Business Daily) +6.24%
Jul-03-23 10:42AM
Aurinia (AUPH) Up on Paving the Way for a Potential Buyout
(Zacks)
Jul-02-23 05:59PM
Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?
(Zacks)
Jun-30-23 04:02PM
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout
(Investor's Business Daily) +5.68%
02:49PM
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
(Motley Fool)
Jun-29-23 04:05PM
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
(Business Wire)
Jun-20-23 09:00AM
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
(Business Wire)
Jun-06-23 08:11AM
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shares Lagging The Industry But So Is The Business
(Simply Wall St.) +5.35%
Jun-01-23 09:00AM
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
(Business Wire)
May-26-23 05:16PM
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
(Business Wire)
May-23-23 06:56AM
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shift From Loss To Profit
(Simply Wall St.)
May-17-23 12:14PM
Aurinia Announces 2023 Annual General Meeting Results
(Business Wire)
May-11-23 12:00PM
Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy
(Zacks)
May-09-23 06:02AM
News Flash: Analysts Just Made A Sizeable Upgrade To Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Forecasts
(Simply Wall St.)
06:00AM
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
(Business Wire)
May-04-23 07:15AM
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
06:11AM
Aurinia: Q1 Earnings Snapshot
(AP Finance)
06:00AM
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
(Business Wire)
May-03-23 07:51AM
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
(Business Wire)
May-02-23 04:36PM
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting
(Business Wire)
12:00PM
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
(Business Wire)
Apr-28-23 06:30AM
Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting
(Business Wire)
Apr-26-23 11:30AM
3 Biotechs That Might Get Bought Out in 2023
(Motley Fool)
Apr-25-23 11:00AM
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
(Business Wire)
Apr-24-23 05:10PM
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
(Benzinga)
06:00AM
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
(Business Wire)
Apr-12-23 12:34PM
Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent
(Zacks)
Apr-11-23 02:41PM
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
(Motley Fool) +10.84%
10:26AM
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
(Business Wire)
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greenleaf PeterChief Executive OfficerMar 06 '24Sale5.60126,981711,0941,522,114Mar 07 04:46 PM
Robertson Stephen P.EVP, General CounselMar 06 '24Sale5.6057,745323,372443,824Mar 07 04:41 PM
Donley Matthew MaxwellEVP, Ops & StrategyMar 06 '24Sale5.5140,665224,064584,072Mar 07 04:43 PM
Miller Joseph MChief Financial OfficerMar 06 '24Sale5.6034,811194,942495,928Mar 07 04:44 PM
Habig Scott MichaelChief Commercial OfficerMar 06 '24Sale5.6017,77799,551474,587Mar 07 04:42 PM
Knappertz VolkerEVP, Research and DevelopmentFeb 27 '24Sale6.104,93030,073319,128Feb 29 04:11 PM
Knappertz VolkerEVP, Research and DevelopmentFeb 20 '24Sale5.4825,146137,800324,058Feb 22 04:35 PM
Habig Scott MichaelChief Commercial OfficerFeb 20 '24Sale5.4815,86786,951492,364Feb 22 04:33 PM
Jayne David R.W.DirectorMay 23 '23Sale11.268,73398,33449,310May 23 05:19 PM
MacKay-Dunn R. HectorDirectorMay 23 '23Sale11.264,81854,25124,225May 23 05:16 PM
Leversage JillDirectorMay 23 '23Sale11.264,81554,21718,528May 23 05:14 PM
Billen DanielDirectorMay 23 '23Sale11.264,65052,35933,393May 23 05:17 PM
Hagan Joseph PDirectorMay 19 '23Sale10.582722,87811,961May 23 05:18 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.